Compare Atmos Energy Corporation (ATO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Atmos Energy Corporation trades at $178.45 (market cap $29.79B), while Regeneron Pharmaceuticals Inc trades at $655.02 (market cap $68.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.3× Atmos Energy Corporation's market cap, and Atmos Energy Corporation pays the higher dividend (2.24%). Which is the better fit depends on your goals.
| ATO | REGN | |
|---|---|---|
Market Cap | $29.79B | $68.79B |
Sector | Utilities | Health |
52-Week High | $192.25 | $812.27 |
52-Week Low | $154.10 | $542.52 |
Enterprise Value | $39.29B | $62.74B |
Dividend Yield | 2.24% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $179.50, up 1.87% on the day, with a bullish technical outlook and strong support near $179. The stock shows solid fundamentals with a P/E of 22.11, revenue of $4.70B in 2025, and net income margin of 27.58%. Recent news highlights its position to benefit from data center demand and regulatory support, with an upcoming Q3 earnings call on August 6, 2026.
The outlook is positive with a consensus price target of $191.00, though risks include high capital expenditures and debt levels. Earnings growth and dividend stability provide upside, but investors should monitor execution on capex plans and interest rate impacts.
Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.
The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
